A micro-cap MedTech with first-to-market weight-bearing CT aims to flip from lumpy hardware to high-margin AI + China royalties—if MAKO validation and FDA clearance land on time.
Overview
CurveBeam AI Limited (CVB.AX) is a medical imaging and diagnostics company combining specialized high-resolution CT hardware with AI-driven clinical software, created in 2022 via the merger of US-based CurveBeam LLC and Australia-based StraxCorp. Operations are split to leverage regional strengths: Hatfield, Pennsylvania serves as the global operations hub (manufacturing, regulatory, marketing), while Melbourne houses AI research, IP management, and corporate finance. The company targets musculoskeletal imaging in large orthopedic and bone health markets, with a commercial focus on enabling “point-of-care” imaging economics for orthopedic practices. Its flagship HiRise™ system is positioned as the first CT platform capable of natural, bilateral weight-bearing CT scans of the full lower extremities (hip-to-foot) and distal upper extremities—providing 3D alignment under physiological load that traditional 2D X-ray or supine CT/MRI can miss. Current revenue is primarily from capital equipment sales (typical unit pricing cited ~US$410k–$460k), supplemented by recurring after-market service contracts and early-stage strategic royalties (Greater China). Management’s core value-creation plan is to build a larger installed base through major distribution partners (notably Stryker in the US and WEGO in China) and then layer on high-margin AI modules; the most advanced is a Bone Mineral Density (BMD) module targeting FDA clearance in mid-2026, with per-scan (~US$90) or subscription monetization and >90% gross margin potential. Commercial momentum improved in FY25 (revenue ~A$12.1m, +86% YoY; 62 unit placements vs 46 prior year), but the company remains in a “growth-to-profitability” phase with material operating losses and funding sensitivity. The investment debate centers on whether the upcoming catalysts—MAKO validation, FDA clearance, and China scale-up—arrive on schedule to justify a re-rating from a discounted hardware multiple to a platform-like mix of hardware + SaaS + royalties.